Related Experiment Video

Updated: Aug 20, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

Andrew J Dannenberg1, Scott M Lippman, Jason R Mann

  • 1Vanderbilt-Ingram Cancer Center, 691 Preston Research Building, 2300 Pierce Avenue, Nashville, TN 37232-6838, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|January 8, 2005
PubMed

Insights

Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are key targets for cancer prevention. Targeting both COX-2 and EGFR together may offer a more effective chemoprevention strategy against cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Carcinogenesis research is vital for developing cancer prevention strategies.
  • Chemoprevention, using drugs or natural compounds to inhibit cancer development, is a growing field.
  • Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are implicated in cancer progression.

Purpose of the Study:

  • To review evidence linking COX-2 and EGFR to carcinogenesis.
  • To explore the mechanisms of action for COX-2 and EGFR in cancer.
  • To strengthen the rationale for combination chemoprevention targeting both pathways.

Main Methods:

  • Literature review of existing data on COX-2, EGFR, and carcinogenesis.
  • Analysis of mechanisms of action and potential crosstalk between COX-2 and EGFR.
  • Overview of a planned clinical trial for combination chemoprevention.

Main Results:

  • Evidence suggests a causal role for COX-2 and EGFR in carcinogenesis.
  • Crosstalk between COX-2 and EGFR pathways is identified.
  • A clinical trial is proposed to test combination chemoprevention.

Conclusions:

  • COX-2 and EGFR are promising pharmacologic targets for cancer chemoprevention.
  • Combination therapy targeting both COX-2 and EGFR warrants further investigation.
  • Clinical trials are necessary to validate the efficacy of combined COX-2 and EGFR inhibition.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: